State Street reports 5.5% stake in Intellia
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of Intellia Therapeutics common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of Intellia Therapeutics common stock. It reports beneficial ownership of 6,418,836 shares, representing 5.5% of the outstanding common stock as of the event date.
State Street reports no sole voting or dispositive power, with shared voting power over 6,045,757 shares and shared dispositive power over 6,418,836 shares. The holdings are reported as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia. Several State Street Global Advisors and related investment adviser subsidiaries are identified as relevant entities.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does State Street Corporation’s Schedule 13G say about its NTLA holdings?
How much of Intellia Therapeutics’ common stock does State Street beneficially own?
Which State Street affiliates are involved in the Intellia Therapeutics position?
Why did State Street file a Schedule 13G for Intellia Therapeutics?
Who signed the State Street Schedule 13G for NTLA and when?
AI-generated analysis. How Rhea-AI works. Not financial advice.